Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study

Abstract

Aim To compare the kinetics of neutralizing antibodies (NΑbs) against SARS-CoV-2 after vaccination with the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) between patients with T2DM and healthy controls. Methods NAb levels after the BNT162b2 mRNA vaccine were compared between 50 patients with non-insulin treated T2DM and 50 age-, gender-, and BMI-matched healthy controls up to 3 months after the second dose. The median age of both groups was 70 years. Results On day 1, mean NAbs of the control and T2DM groups were 14.64% (standard error, SE = 2.30) and 14.04% (SE = 2.14), respectively (p value = 0.926). Three weeks later, the mean NAb values were 39.98% (SE = 3.53) in the control group and 40.97% (SE = 3.99) in participants with T2DM (p value = 0.698). One month after the second vaccination, mean NAb values increased to 87.13% (SE = 2.94) in the control group and 89.00% (SE = 2.18) in the T2DM group. Three months after the second vaccine dose, the mean inhibitory titers decreased to 83.49% (SE = 3.82) (control group) and 76.36% (SE = 3.33) (T2DM group). On all occasions, no significant difference was found between the two groups (all p values > 0.05). Conclusions Patients with T2DM present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to that of healthy subjects.

Patients with type 2 diabetes mellitus and response to COVID-19 BNT162b2 mRNA vaccine: correspondence

“…org/ 10. 1007/ s42000-022-00405-7) [1]." Focusing their study on patients following their immunization with the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioN-Tech), the kinetics of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with T2DM and healthy controls were examined and compared [1].…”

“…1007/ s42000-022-00405-7) [1]." Focusing their study on patients following their immunization with the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioN-Tech), the kinetics of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with T2DM and healthy controls were examined and compared [1]. According to their report, patients with T2DM have an immune response to the COVID-19 BNT162b2 mRNA vaccination that is comparable to that of healthy participants [1].…”

COVID-19, diabetes mellitus type 2, endocrine genetics, and pituitary and adrenal diseases

“…As mentioned last summer [1], Hormones continues to have keen interest in COVID-19, the endocrine morbidity associated with it, as well as what was initially called "long-COVID-19" syndrome, also known as "post-COVID-19 conditions" (PCC): the latter condition may, in fact, be in large part due to hormonal dysfunction [2]. The current issue of Hormones features reports and correspondence on the administration of the COVID-19 BNT162b2 mRNA vaccine, publications that add significantly to the field [3][4][5][6]. It is truly amazing what we are learning today about both the disease and the vaccinations together with their possible long-lasting effects.…”